Read by QxMD icon Read


Colten Wendel, Helena Zakrzewski, Bruce Carleton, Mahyar Etminan, Frederick S Mikelberg
PURPOSE: To determine the association of post-operative topical prostaglandin analog (PGA) or topical beta-blocker use and the incidence of pseudophakic cystoid macular edema (CME). METHODS AND PATIENTS: This was a nested case control study. All adult patients who underwent cataract surgery between January 1, 2006 and December 31, 2016 and who were enrolled in the PharMetrics Plus database were eligible for inclusion. The association between post-operative topical PGAs (bimatoprost, latanoprost and travoprost/travoprost-z) or beta-blocker (betaxolol, levobunolol and timolol) use and the incidence of pseudophakic CME was assessed by conditional logistic regression...
March 2, 2018: Journal of Glaucoma
Nongsak Chanasumon, Tueboon Sriphojanart, Poonkiat Suchonwanit
Eyebrows serve as a key feature of the face and have many roles, including cosmetic appearance and social communication. Eyebrow hypotrichosis, which refers to reduction or absence of the eyebrow hair, could be a major problem that leads to negative functional, psychological, and social consequences. Bimatoprost is an ophthalmic prostamide analog that is approved by the United States Food and Drug Administration for the treatment of eyelash hypotrichosis. Its proposed mechanism is stimulation of the prostaglandin receptor in dermal papilla and melanocyte, thus leading to a prolonged anagen phase and increased melanogenesis...
2018: Drug Design, Development and Therapy
Susan S Lee, James Burke, Jie Shen, Alexandra Almazan, Werhner Orilla, Patrick Hughes, Jane Zhang, Huajiang Li, Craig Struble, Paul E Miller, Michael R Robinson
OBJECTIVE: To determine the effect of a bimatoprost sustained-release intracameral implant (Bimatoprost SR) on episcleral venous pressure (EVP) in normal dogs. METHODS: Normotensive beagle dogs were randomized to receive Bimatoprost SR 30 μg (n = 7) or sham injection (needle insertion only, n = 7) in one eye on day 1. EVP was measured with an episcleral venomanometer through day 65. Episcleral aqueous outflow vessels were identified using fluorescence imaging following intracameral injection of indocyanine green in one additional animal...
February 19, 2018: Veterinary Ophthalmology
Seema Sharma, Davindar Parsad, Rajsmita Bhattacharjee, Sendhil Kumaran Muthu
The treatment of vitiligo has been a tough challenge for dermatologists. Phototherapy, apart from being first line monotherapy,1has also been used in combination with topical therapies like corticosteroids, khellin, phenylalanine, calcineurin inhibitors etc, with the aim of hastening and enhancing repigmentation and reducing side-effects.2,3Recent reports have highlighted darkening of iris, and eyelash and periocular hyperpigmentation induced by latanoprost (prostaglandin F2α analogue) used for treatment of glaucoma...
February 14, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
Luca Agnifili, Rodolfo Mastropasqua, Vincenzo Fasanella, Lorenza Brescia, Barbara Scatena, Francesco Oddone, Leonardo Mastropasqua
PURPOSE: To investigate, using in vivo confocal microscopy (IVCM), the Meibomian gland (MG) features and conjunctival goblet cell density (GCD) in glaucomatous patients controlled with prostaglandin/timolol fixed combinations (PTFCs). METHODS: In this cross-sectional study, sixty Caucasian patients treated with PTFCs, fifteen with latanoprost+timolol (L+T) unfixed combination, and fifteen controls were enrolled. Patients underwent the Ocular Surface Disease Index (OSDI) questionnaire, tear film break-up time (BUT), corneal staining, Schirmer test I (STI), and IVCM of MGs and goblet cells (GCs)...
February 2, 2018: Journal of Glaucoma
Susan H Weinkle, W Philip Werschler, Craig F Teller, Jonathan M Sykes, Ava Shamban, Alexander Rivkin, Vic A Narurkar, Michael S Kaminer, Steven Dayan, Joel L Cohen, Conor J Gallagher
Background: Individuals seeking aesthetic treatment have concerns regarding multiple facial areas. Objectives: Assess the aesthetic impact and satisfaction achieved with a multimodal approach to aesthetic treatment using a combination of minimally invasive treatments. Methods: Prospective, multicenter, rater-blinded, 4-month HARMONY study evaluated patient satisfaction and aesthetic impact of a combination of fillers (VYC-20L, HYC-24L, and HYC-24L+), onabotulinumtoxinA, and bimatoprost...
December 13, 2017: Aesthetic Surgery Journal
Ferdinand Rodríguez-Agramonte, Juan Carlos Jiménez, José Raúl Montes
OBJECTIVE: To describe the prevalent side effects of prostaglandin analogues (PA) in a Hispanic population and their effect on quality of life (QOL). PATIENTS AND METHODS: This is a cross-sectional study conducted in a tertiary medical facility in which patients were evaluated in a single visit. Total of 14 participants in the study, 10 women and 4 men. Ages ranged from 26-78 years old. Subjects underwent a single full Oculoplastic evaluation by two physicians; one was blinded on patient medical history and assessed for PA side effects...
December 2017: Puerto Rico Health Sciences Journal
Suk Bae Moon, Sang Beom Han
No abstract text is available yet for this article.
2017: Patient Preference and Adherence
Gabriel Lazcano-Gomez, Daniela Alvarez-Ascencio, Cindy Haro-Zuno, Mauricio Turati-Acosta, Magdalena Garcia-Huerta, Jesus Jimenez-Arroyo, Rafael Castañeda-Diez, Armando Castillejos-Chevez, Roberto Gonzalez-Salinas, Francisca Dominguez-Dueñas, Jesus Jimenez-Roman
Aim: To determine the glaucoma specialists' preferences for the different brands of topical glaucoma medications available in Mexico. Materials and methods: A web-based survey was sent to 150 board-certified glaucoma specialists in Mexico, with 14 questions related to brand preferences for all glaucoma medications available in Mexico. Participants were asked to select each glaucoma medication class by brand and to state the factors leading to their choice. Results: Data from 111 (74%) glaucoma specialists were collected...
September 2017: Journal of Current Glaucoma Practice
Ji Hyun Lee, Gihaeng Kang, Han Na Park, Jihee Kim, Nam Sook Kim, Seongsoo Park, Sung-Kwan Park, Sun Young Baek, Hoil Kang
In this study, we developed a UPLC-PDA and LC-Q-TOF/MS method to identify and measure the following prohibited substances that may be found in dietary supplements:triaminodil, minoxidil, bimatoprost, alimemazine, diphenylcyclopropenone, α-tradiol, finasteride, methyltestosterone, spironolatone, flutamide, cyproterone, dutasteride, and testosterone 17-propionate.The method was validated according to International Conference on Harmonization guidelines in terms of specificity, linearity, accuracy, precision, LOD, LOQ, recovery, and stability...
December 14, 2017: Food Additives & Contaminants. Part A, Chemistry, Analysis, Control, Exposure & Risk Assessment
Curt Hartleben, Juan Camilo Parra, Amy Batoosingh, Paula Bernstein, Margot Goodkin
OBJECTIVE: To evaluate the efficacy and safety of triple fixed-combination bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% (TFC) versus dual fixed-combination brimonidine 0.2%/timolol 0.5% (DFC) in primary open-angle glaucoma and ocular hypertension. METHODS: Patients with intraocular pressure (IOP) ≥23 and ≤34 mmHg were randomized to twice-daily TFC or DFC. The primary variable is the change in worse eye mean IOP from baseline at week 12 (modified intent-to-treat (mITT) population)...
2017: Journal of Ophthalmology
Abhijeet K Jha, Smita Prasad, Rajesh Sinha
BACKGROUND: Vitiligo is one of the commonest pigmentary disorders characterized by destruction of melanocytes. AIM: To evaluate the efficacy of topical bimatoprost ophthalmic solution in stable facial vitiligo. MATERIAL AND METHODS: Eight cases of stable facial vitiligo were treated with bimatoprost 0.03% ophthalmic solution once daily for 12 weeks. Photographic records were taken at 2 weeks follow-up along with dermoscopic (Polarized, 10×) evaluation...
October 15, 2017: Journal of Cosmetic Dermatology
Jie Shen, Margot L Goodkin, Warren Tong, Mayssa Attar
PURPOSE: Fixed-combination medications can benefit patients requiring multiple agents to lower their intraocular pressure (IOP), but combining agents with complementary mechanisms of action is challenging if their dosing frequency differs. This study compares in vivo pharmacokinetic and ocular tolerability of bimatoprost 0.01% ophthalmic solutions dosed once or twice daily. Reports of twice-daily dosing in glaucoma patients are also reviewed. METHODS: New Zealand White rabbits were administered bimatoprost 0...
2017: Clinical Ophthalmology
O N Kuleshova, E A Pichikova, A K Lasareva, S V Aydagulova, V V Dulidova, E V Egorova, V V Chernykh
Epidemiological investigation of pseudoexfoliative syndrome (PEX) as a glaucoma predictor is necessary for antiglaucoma treatment planning. AIM: To study the prevalence of PEX and pseudoexfoliative glaucoma (PXFG) among healthy people, naïve patients, and patients under observation as well as to evaluate the hypotensive efficacy of bimatoprost/timolol fixed combination (FCBT) over 4 months in PXFG. MATERIAL AND METHODS: Epidemiological analysis, ophthalmological examination, statistical analysis...
2017: Vestnik Oftalmologii
Ashley Regis, Jennifer MacGregor, Anne Chapas
No abstract text is available yet for this article.
September 28, 2017: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
Nicholas Brennan, Mohammad H Dehabadi, Sandhya Nair, Ana Quartilho, Catey Bunce, Ian Reekie, Raal Obikpo
AIM: To establish the efficacy and safety of bimatoprost 0.03% monotherapy in glaucoma and ocular hypertension (OHT) patients with inadequate intraocular pressure (IOP)on current therapy. METHODS: Pre- and post-switch IOPs were analyzed for 59 consecutive patients who were switched from current therapy to bimatoprost monotherapy between 2011-2015. Demographic information, diagnosis, and any adverse events were recorded. Change in IOP post-pre switch was analyzed using a 2-sided Student's paired t-test at the 5% significance level...
2017: International Journal of Ophthalmology
Sarita S Deshpande, Sriram Sonty, Afzal Ahmad
PURPOSE: The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of bimatoprost 0.01% solution in patients with primary open-angle glaucoma (POAG), who were switched from bimatoprost 0.03% solution, compared to patients with POAG who continued on bimatoprost 0.03% solution. METHODS: A retrospective review evaluated 35 patients (35 right eyes [OD], 34 left eyes [OS]) who remained on bimatoprost 0.03% and 30 patients (27 OD, 30 OS) who were switched to bimatoprost 0...
2017: Clinical Ophthalmology
Daniel Lee, Anand V Mantravadi, Jonathan S Myers
Glaucoma is a leading cause of irreversible blindness worldwide. The reduction of intraocular pressure has been well established as an effective treatment to prevent both the development and the progression of all forms of glaucoma. Bimatoprost 0.03% ophthalmic solution, introduced in 2001, is a synthetic prostamide with the unique mechanism of improving both uveoscleral and trabecular outflow. Comparative studies with other pharmacotherapies have shown favorable results for bimatoprost as a potent ocular hypotensive agent that is generally well tolerated...
2017: Clinical Ophthalmology
Takako Miki, Tomoko Naito, Miyuki Fujiwara, Ryoichi Araki, Rieko Kiyoi, Yusuke Shiode, Atsushi Fujiwara, Yuki Morizane, Fumio Shiraga
For primary open angle glaucoma (POAG), laser treatment or surgery is used when the target intraocular pressure (IOP) cannot be achieved by pharmacological agents, such as prostaglandin (PG) analogs; these drugs also have varied effects. We retrospectively reviewed the medical records of 74 POAG patients (74 eyes) whose IOP was inadequately controlled by PG analogs (bimatoprost [13 eyes], latanoprost [34 eyes], tafluprost [11 eyes], and travoprost [16 eyes]) and underwent primary trabeculectomy. The proportion of patients with no recurrent IOP elevation within 24 months post-trabeculectomy was significantly (P < 0...
2017: PloS One
Hee Weon Kim, Youn Joo Choi, Kyung Wha Lee, Min Joung Lee
BACKGROUND: Prostaglandin analogs (PGAs) are commonly used to treat glaucoma because of their powerful intraocular pressure lowering effect. However, various periorbital changes associated with the use of PGAs have been reported. We investigated the incidence of periorbital changes in Korean patients who were treated with PGAs, and analyzed clinical factors associated with superior sulcus deepening. METHODS: This study included 58 glaucoma patients who were treated with latanoprost, travoprost, or bimatoprost unilaterally...
July 17, 2017: BMC Ophthalmology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"